5%)存在EGFR基因突变,腺癌高于非腺癌;不吸烟患者高于吸烟患者;女性患者高于男性患者;差异均有统计学意义(均0.05)。结论 NSCLC患者中,EGFR及EML4-ALK阳性患者在临床病理上有一些相同或相似的特征,即女性、非吸烟、腺癌患者中较为多见,但也有一些不同的特征:EML4-ALK阳性患者中,腺癌中多伴有黏液产生的腺泡样结构,不同时合并EGFR突变。
Cluster

一般 of differentiation 74(CD74) performs multiple roles in B cells,T cells,and antigen-presenting cells within the immune system; it also participates in major histocompatibility complex class Ⅱ-restricted antigen presentation and inflammation. Recently,a role for CD74 in carcinogenesis has been described. CD74 promotes cell proliferation and motility and prevents cell death in a macrophage migration inhibitory factordependent manner. Its roles as an accessory signal receptor on the cell surface and the ability to interact with other signaling molecules

make CD74 an attractive therapeutic target for the treatment of cancer. This review focuses on the original role of CD74 in the immune system and its emerging tumor-related functions. First,the structure of CD74 will be summarized. Second,the current understandings about the expression,cellular localization,molecular 这个 mechanisms and signaling pathways of CD74 in immunity and cancerwill be reviewed. Third,the examples that suggest CD74 is a promising molecular therapeutic target are reviewed and discussed. Although the safety and efficacy of CD74-targeted strategies are under development,deeply understanding of the regulation of CD74 will hold promise for the use of CD74 as a therapeutic target and may develop the CD74-targeted therapeutic agents such as neutralized antibody and compounds.
脑是非小细胞肺癌常见的转移部位,手术和放疗是以往脑转移治疗的基石,但近年来随着对肿瘤发生发展机制的认识深化,靶向治疗在脑转移治疗中开始崭露头角。本文主要针对一些相关热点问题如脑转移治疗手段等(手术、放疗、化疗、靶向治疗)进行简要述评。
~~
Lung 此网站 cancer, is the most

common cause of cancer death in men and second only to breast cancer in women. Currently, the first line therapy of choice is platinumbased combination chemotherapy. A therapeutic plateau has been reached with the prognosis for patients with advanced non-small cell lung cancer(NSCLC) remaining poor. New biomarkers of prognosis as well as new therapies focusing on molecular targets are emerging helping to identify patients who are likely to benefit from therapy. Despite this, drug resistance remains the major cause for treatment failure. In this article we review the role of apoptosis in mediating drug resistance in NSCLC.